Peptide Education
What Is Sermorelin? The Original GHRH Peptide
Sermorelin was the first growth hormone–releasing hormone (GHRH) analog to become an FDA-approved drug. The brand, Geref, was later discontinued for business reasons, but sermorelin is still widely discussed and prescribed through compounding pharmacies. This guide explains what sermorelin is, how it works, what the evidence shows, and how it compares to newer GHRH analogs.
Reviewed for accuracy · Last reviewed October 19, 2026
What Is Sermorelin?
Sermorelin is a synthetic peptide made of the first 29 amino acids of human GHRH, sometimes written as GHRH(1-29). Researchers found that this short piece carries the full activity of the 44-amino-acid natural hormone.
It was approved by the FDA as Geref (Serono) for diagnosing and treating growth hormone deficiency in children. The manufacturer later withdrew Geref from the U.S. market for commercial reasons, not because of safety problems.
How Does Sermorelin Work?
Sermorelin binds to the GHRH receptor in the pituitary gland, prompting it to make and release growth hormone (GH). GH then signals the liver to produce IGF-1.
- Works with natural feedback: because it acts upstream of GH, the body’s own brakes, such as somatostatin and IGF-1 feedback, still apply.
- Short-acting: sermorelin is broken down within minutes, so it produces a brief GH pulse rather than a constant level.
- Depends on a working pituitary: it can only increase GH if the pituitary is able to respond.
This is the main difference from taking growth hormone itself, which bypasses those controls.
What Does the Research Show?
Children with GH deficiency. Clinical trials in the 1990s showed that sermorelin increased growth rates in some children with growth hormone deficiency, which supported its approval. It was generally less effective than direct GH treatment.
Older adults. Small studies in older men and women found that sermorelin raised GH and IGF-1 levels. Some reported modest changes in lean body mass, skin thickness or well-being, but results were inconsistent and the studies were small and short.
What is missing. There are no large, long-term trials showing that sermorelin improves body composition, strength or longevity in healthy adults.
| Area | What studies show | Evidence type |
|---|---|---|
| GH deficiency in children | Increased growth rate | Clinical trials (basis of approval) |
| GH and IGF-1 in older adults | Levels increased | Small human studies |
| Body composition in adults | Modest, inconsistent changes | Small human studies |
| Long-term outcomes | Not studied | Lacking |
Sermorelin Side Effects
In clinical use, sermorelin was generally well tolerated. Reported side effects include:
- Injection-site pain, redness or swelling (the most common)
- Facial flushing and headache
- Dizziness or nausea
- Rarely, allergic reactions
Like other GH-raising treatments, it is generally avoided in people with active cancer and needs medical oversight in people with diabetes or thyroid problems.
Is Sermorelin FDA-Approved?
Sermorelin was FDA-approved as Geref, but the branded product is no longer sold in the U.S. Because it was withdrawn for business rather than safety reasons, sermorelin is still prescribed in the U.S. through licensed compounding pharmacies. It is not on the FDA’s list of compounding ingredients that may present significant safety risks.
Research-grade sermorelin from peptide suppliers is a different product: it is sold for laboratory use only and is not made under pharmacy or drug standards. Sermorelin is also prohibited in sport by WADA.
Sermorelin vs Tesamorelin vs CJC-1295
| Compound | Structure | Half-life | Status |
|---|---|---|---|
| Sermorelin | Natural GHRH 1-29 | Minutes | Formerly approved (Geref); compounded |
| Tesamorelin | Full GHRH 1-44 with a stabilizing group | About 30 minutes | FDA-approved (Egrifta) for HIV-associated abdominal fat |
| CJC-1295 no DAC (Mod GRF 1-29) | GHRH 1-29 with four swaps | About 30 minutes | Not approved |
| CJC-1295 with DAC | Mod GRF 1-29 plus albumin linker | About a week | Not approved |
Sermorelin vs tesamorelin. Tesamorelin is more stable and has strong phase 3 evidence for reducing visceral (deep belly) fat in people with HIV. Sermorelin has a longer history but weaker modern trial data.
Sermorelin vs ipamorelin. Ipamorelin acts on a different receptor (the ghrelin receptor). Some clinics combine a GHRH analog with a ghrelin-receptor agonist because the two pathways work together.
Buying Research-Grade Sermorelin: What to Check
Products sold as Sermorelin by research suppliers are laboratory chemicals, not medicines. They are not made under drug manufacturing rules, so quality varies a lot between vendors. If you are evaluating a Sermorelin supplier for lab research, these are the checks that matter:
- Batch-specific COA: the certificate should match the lot number on your vial, not a generic sample.
- Independent lab: testing should come from a named third-party lab, ideally with a way to verify the report online.
- Identity, not just purity: HPLC purity alone does not confirm the right molecule; look for mass spectrometry (MS) identity confirmation.
- Endotoxin and sterility results: these matter for any injectable research material.
- Correct fill amount: the measured content should be close to the labeled milligrams.
Our Trusted Sources page lists vendors we track, with current community codes. Our guide to reading a certificate of analysis explains each line of a COA.
Key Takeaways
- Sermorelin is the first 29 amino acids of GHRH, the hormone that triggers GH release.
- It was FDA-approved as Geref for children with GH deficiency, then withdrawn for business reasons.
- It raises GH and IGF-1 while keeping the body’s natural feedback controls.
- Evidence in healthy adults is limited and inconsistent.
- It is prescribed through compounding pharmacies; research-grade products are not the same.
Frequently Asked Questions
What is sermorelin?
Sermorelin is a synthetic peptide made of the first 29 amino acids of growth hormone–releasing hormone (GHRH). It signals the pituitary to release growth hormone.
Is sermorelin FDA-approved?
It was approved as Geref for children with growth hormone deficiency, but the brand was withdrawn for business reasons. It is still prescribed through compounding pharmacies.
Is sermorelin the same as growth hormone?
No. Sermorelin stimulates your own pituitary to release growth hormone, while GH injections replace the hormone directly.
What is the difference between sermorelin and tesamorelin?
Both are GHRH analogs. Tesamorelin is more stable and is FDA-approved for HIV-associated abdominal fat, with stronger modern trial evidence.
What are the side effects of sermorelin?
Mostly injection-site reactions, plus flushing, headache and dizziness. Serious side effects were uncommon in clinical use.
Sources
- Walker (2006) – Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?, Clinical Interventions in Aging
- Thorner et al. (1996) – Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient children
- Khorram et al. (1997) – Effects of GHRH(1-29)NH2 administration in age-advanced men and women
- FDA – Certain bulk drug substances for use in compounding that may present significant safety risks (updated April 22, 2026)
MLCR SCTY provides educational information, not medical or legal advice. Research-use-only products are not intended for human consumption.